Parthenon LLC Reduces Position in Medtronic PLC $MDT

Parthenon LLC decreased its stake in shares of Medtronic PLC (NYSE:MDT) by 17.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,969 shares of the medical technology company’s stock after selling 15,268 shares during the quarter. Parthenon LLC’s holdings in Medtronic were worth $6,854,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in MDT. Sovran Advisors LLC raised its stake in shares of Medtronic by 31.0% in the third quarter. Sovran Advisors LLC now owns 6,934 shares of the medical technology company’s stock worth $631,000 after purchasing an additional 1,639 shares during the last quarter. Intact Investment Management Inc. boosted its position in Medtronic by 132.6% in the third quarter. Intact Investment Management Inc. now owns 93,500 shares of the medical technology company’s stock valued at $8,905,000 after buying an additional 53,300 shares during the last quarter. Keynote Financial Services LLC increased its holdings in Medtronic by 17.7% in the 3rd quarter. Keynote Financial Services LLC now owns 9,023 shares of the medical technology company’s stock worth $859,000 after buying an additional 1,354 shares during the period. Commerzbank Aktiengesellschaft FI increased its holdings in Medtronic by 33.4% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 39,167 shares of the medical technology company’s stock worth $3,731,000 after buying an additional 9,811 shares during the period. Finally, Sector Gamma AS raised its position in Medtronic by 35.5% during the 3rd quarter. Sector Gamma AS now owns 303,441 shares of the medical technology company’s stock worth $28,900,000 after buying an additional 79,441 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MDT has been the topic of several recent research reports. UBS Group upped their price objective on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday, November 19th. Royal Bank Of Canada upped their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Stifel Nicolaus boosted their price objective on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Finally, Sanford C. Bernstein upped their target price on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Fourteen investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Trading Down 0.4%

Shares of Medtronic stock opened at $100.98 on Monday. The firm has a 50-day simple moving average of $99.44 and a two-hundred day simple moving average of $95.32. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a market cap of $129.45 billion, a P/E ratio of 27.22, a price-to-earnings-growth ratio of 2.66 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).